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Available online 4 January 2012Abstract Deficiency of the nuclear factor-kappa-B essential modulator (NEMO) is a rare X-linked disorder that presents in
boys as hypohydrotic ectodermal dysplasia with immunodeficiency due to defective nuclear factor-κB activation. Here we
report on the generation of 2 human embryonic stem cell lines from discarded in vitro fertilization (IVF) embryos ascertained
via preimplantation genetic diagnosis. We have derived two human embryonic stem cell lines that carry a T458G hypomorphic
mutation in exon 4 of the NEMO (or IKBKG) gene. One of the lines is diploid male; the other is diploid female but has clonally
inactivated the X-chromosome that harbors the wild-type IKBKG gene. We show that both lines are pluripotent, have the
capacity to differentiate into hematopoietic progenitors, and have defective inhibitor of nuclear factor kappa-B kinase
activity. These NEMO deficiency hES cell lines provide an unlimited source for differentiated cell types and may serve as a
unique tool to study NEMO deficiency and potentially lead to the development of new therapies for this disease.
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411Derivation of human embryonic stem cells with NEMO deficiencyIntroduction
Mutations in the IKBKG gene, which encodes the nuclear
factor-κB (NF-κB) essential modulator (NEMO), can result
in ectodermal dysplasia and immunodeficiency (Doffinger
et al., 2001; Hanson et al., 2008; Jain et al., 2001; Zonana
et al., 2000). NEMO, also known as inhibitor of nuclear factor
kappa-B kinase subunit gamma (IKK-γ), binds IKK-α and IKK-
β to form the IκB kinase (IKK) complex. Activation of the IKK
complex leads to phosphorylation and degradation of IκBα,
which then allows NF-κB to translocate into the nucleus
where it carries out transcriptional regulation (Gilmore,
2006). NEMO deficient mouse embryos die around E12.5
to E13 due to severe liver degeneration and apoptosis
induced by lack of NFkB activation (Rudolph et al., 2000).
In humans, while null mutations in the X-linked NEMO
gene are lethal to males, hypomorphic mutations including
T458G cause diverse clinical and immunological phenotypes
(Hanson et al., 2008). The immunodeficiency caused by
these mutations is characterized by susceptibility to myco-
bacterial and streptococcal infections, dysgammaglobuline-
mia, poor polysaccharide-specific antibody responses,
depressed antigen-specific lymphocyte proliferation and
defects in natural killer cell cytotoxicity (Abinun et al.,
1996; Clarke et al., 1987; Doffinger et al., 2001; Huntley
and Ross, 1981; Jain et al., 2001; Orange et al., 2002;
Zonana et al., 2000).
In preimplantation genetic diagnosis (PGD), a blastomere
aspirated from an in vitro fertilized (IVF) embryo at the 8-
cell stage undergoes genetic testing. The results of the
testing are completed in 48 h or less, sufficient time to
select unaffected embryos to transfer to the uterus to
avoid transmitting a genetic disorder to a couple's offspring.Nanog
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Figure 1 Staining for pluripotency associated proteins. Intracellula
SSEA-4, Tra-1-60) and alkaline phosphatase (AP).Embryos that test positive for a genetic disorder are typical-
ly discarded. Derivation of human embryonic stem (hES) cell
lines for research is an alternative use for embryos deemed
unsuitable for clinical use (Lerou et al., 2008b). hES cells,
an immortal source of pluripotent cells that theoretically
can generate any cell type within the human body, allow in-
vestigators to study early human development and aspects
of tissue differentiation. Embryos known to carry genetic
diseases by PGD can yield stem cell lines that model single-
gene disorders (Mateizel et al., 2006; Verlinsky et al., 2005).Results
We obtained Institutional Review Board and Embryonic
Stem Cell Research Oversight committee approval at the
Brigham & Women's Hospital and Children's Hospital Boston
to enroll couples undergoing in vitro fertilization (IVF) in a
study for stem cell derivation using donated embryos that
were deemed unsuitable for either uterine transfer or cryo-
preservation. The couple that donated the embryos used in
this study had a previous child with hypohydrotic ectodermal
dysplasia with immunodeficiency due to point mutation
(T458G) in exon 4 of the nuclear factor-κB essential modula-
tor (NEMO, IKBKG) gene (Orange et al., 2002). Polymerase
chain reaction based testing was performed on this couple's
IVF embryos at the 8-cell stage. Based on testing results
and morphologic grading, 12 embryos were deemed unsuita-
ble for clinical use and transferred to our laboratory for hES
cell line derivation. Two lines were established, CHB-13 and
CHB-14. In addition to exhibiting hES cell morphology and
growth characteristics, the cells are alkaline phosphatase
positive and express hES cell-specific cell surface markersNanog
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412 X. Guan et al.and pluripotency genes (Fig. 1 and see Fig. S1A in the Online
Repository). Teratoma-like tissue composed of elements
of all embryonic germ layers formed when each line was
injected intramuscularly into immunocompromised mice
(Fig. 2A). Both lines can undergo robust directed hematopoi-
etic differentiation (Fig. 2B). Karyotyping revealed that
CHB-13 is diploid male and CHB-14 is diploid female (see
Fig. S1B in the Online Repository). DNA fingerprinting using
16 loci further demonstrated a unique genetic identity for
each line (see Fig. S1C in the Online Repository). We con-
firmed the presence of the T458G mutation in the NEMO
gene in both hES cell lines (see Fig. S2 in the Online Reposito-
ry). Hemizygous males, like CHB-13, appear to be heterozy-
gous on this analysis due to presence of a non-expressed
IKKG pseudogene (Zonana et al., 2000).CHB-13 
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Figure 2 Differentiation of NEMO deficient hES cells. A. Teratoma
B. Hematopoietic progenitor assay: Quantification of hematopoietic
of each CFU type. E=Burst forming unit-erythroid. G=CFU-granulo
GEMM=CFU-granulocyte, erythrocyte, macrophage, and megakary
each line tested. CHB-6 is a wild-type hES cell control. Error bars reNext, we set out to characterize the kinase activity of the
IKK complex which when activated leads to phosphorylation
and degradation of IκBα, allowing NF-κB to translocate to
the nucleus and activate its target genes. IκBα expression
and activity are low in undifferentiated hES cells (data not
shown), but can be increased by retinoic acid (RA) induced
differentiation (Kang et al., 2007). After RA induced differ-
entiation in both CHB-13 and CHB-14, treatment with TNFα
failed to induce the degradation of IκBα (Fig. 3), whereas
in the control CHB-6 hES cell line IκBα was rapidly degraded.
Because the male cell line CHB-13 carries the mutated allele
of NEMO on its single X chromosome, we anticipated defi-
cient NEMO activity. However, the female cell line CHB-14
carries both the wild type and the mutated NEMO allele,
yet demonstrated the same degree of NEMO deficiency asrosettes / 
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Figure 3 Western blot analysis for IκBα degradation after TNFα treatment. Human ES cell lines were differentiated for 10 days with
retinoic acid (RA) followed by a treatment course with TNFα (10 ng/ml). Degradation of IκBα is abrogated in CHB-13 and CHB-14.
CHB-6, wild type hES cell control. Beta actin, loading control. TNFα treated HeLa cell lysates serve as additional controls.
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the NEMO gene in this line, which was facilitated by the fact
that the T458G NEMO mutation eradicates an AluI restriction
site (Fig. 4A). When we performed RT-PCR followed by AluI
digestion from cDNA generated from CHB-13 or CHB-14, the
PCR product was completely digested in wild type control
cells, but left intact in both the male CHB-13 and female
CHB-14 line, indicating monoallelic expression of the mutant
gene even in the female cells (Fig. 4B).Discussion
We have derived hES cell lines harboring the T458G mutation
in the NEMO gene from PGD embryos. Both lines express
markers of pluripotency and upon differentiation generate
tissue representative of the 3 embryonic layers. Moreover,WT: ... ggggagctgcaggaga...
... cccctcgacgtcctct...
Mutation: ... ggggagcggcaggaga...
... cccctcgccgtcctct...
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Figure 4 NEMO gene expression analysis for transcripts. A.
The T458G NEMO mutation is restriction site-specific by removing
an AluI site present in the wild type gene. B. RT-PCR was
performed across a 175 bp region spanning the NEMO mutation
followed by AluI digestion. PCR product obtained using
template RNA from CHB-13 (passage 13) and CHB-14 (passage
33) failed to digest with AluI. H9 is a female, wild-type hES
cell control (Thomson et al., 1998).we demonstrated that both lines have potential robust
directed hematopoietic differentiation. CHB-13's karyotype
is a normal diploid male karyotype, while CHB-14's karyotype
is normal diploid female. Despite the fact that this mutation
is X-linked recessive, NEMO deficiency was demonstrated
in both lines, by failure of TNFα treatment to induce IκBα
degradation. While X chromosome inactivation (XCI) is
thought to be random during development, hES cell lines
undergo variable XCI by unclear mechanisms (Hall et al.,
2008; Shen et al., 2008; Silva et al., 2008), although it ap-
pears that during hES cell culture there is clonal selection
as evidenced by monoallelic expression of X-linked genes
(Lengner et al., 2010; Shen et al., 2008). Our findings lend
additional support to this notion. We failed to detect wild
type allelic expression at passages 15 and 33 (Fig. 4B and
see Fig. S3 in the Online Repository). Primary ES cell cultures
tend to be derived from a small number of founder cells
within the inner cell mass but colony picking and expansion
tends to select for clonal outgrowths (Egli et al., 2009).
Thus, while we cannot completely exclude the presence of
a small residual population of cells expressing the wild type
allele, during the derivation and expansion of CHB-14 we
have isolated a line that has inactivated the X chromosome
harboring the wild type NEMO allele.
With the advent of factor-based reprogramming, induced
pluripotent stem cells can be readily obtained from patients
with a variety of genetic diseases (Dimos et al., 2008; Park
et al., 2008; Takahashi and Yamanaka, 2006), but several
limitations exist to factor based reprogramming as models
for disease (Zhu et al., 2011). In addition to the fact that
iPS derivation is technically more difficult, iPS cells may
have genetic and epigenetic anomalies that could also nega-
tively impact efforts at directed differentiation (Gore et al.,
2011; Hussein et al., 2011; Raya et al., 2009). Thus there are
advantages to retaining both human embryonic stem cells
and induced pluripotent stem cells in the armamentarium
of investigators attempting to both study the earliest aspects
of developmental disease as well as unlock the therapeutic
potential of pluripotent stem cells.
Methods
Animals
Rag−/− Gamma C−/−mice were purchased from Taconic. All
experiments were performed in accordance with guidelines
and regulations and approved by the Children's Hospital,
Boston Institutional Animal Care and Use Committee.
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Informed consent was obtained from patients undergoing
IVF therapy at Brigham & Women's Hospital, Boston. Study
protocols were approved by the Institutional Review Board
and Embryonic Stem Cell Research Oversight Committee at
Children's Hospital Boston and Brigham & Women's Hospital.
Embryonic stem cell derivation
hES cell line derivation, expansion, characterization and
genotyping were performed as previously described (Lerou
et al., 2008a,b).
Immunofluorescent staining
hES cell colonies were stained for OCT4, NANOG, TRA-1-60,
TRA-1-81, SSEA3, and SSEA4, as previously described (Lerou
et al., 2008a,b).
Protein analysis
Western blotting analysis was carried out using a rabbit poly-
clonal antibody against IκB (1:1000; Cell Signaling Technology)
followed by a horseradish peroxidase-conjugated goat anti-
rabbit IgG (H&L) (1:10000; Cell Signaling Technology).
Genotyping
Genomic DNA was extracted using DNeasy kit (QIAGEN). The
IKBG locus was amplified and then sequenced. Amplification
primers: forward 5′-ctggggcctgtgtttactttgccc-3′; reverse
5′-gggcgctgacaggacctgccccca-3′. Sequencing primers: for-
ward 5′-cagtgctgacaggaagtggc-3′; reverse 5′-aaccctggaaggg-
gtctccggag-3′.
Blood differentiation
hES cells cultured on MEFs were collected as large aggre-
gates and resuspended in blood differentiation media:
KO-DMEM (Invitrogen), 20% fetal bovine serum (Stem Cell
Technologies), 100 μM non-essential amino acid (Invitrogen),
200 μM L-glutamine (Invitrogen), 50 μg/ml ascorbic acid
(Sigma), 200 μg/ml h-Transferrin (Sigma) and 100 μM 2-
Mercaptoethanol (Sigma). After 24 h, human SCF (300 ng/ml),
Flt3 (300 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), G-CSF
(50 ng/ml) and BMP4 (50 ng/ml) were added. Media containing
cytokines was replaced every 3 days. Embryoid bodies (EBs)
were cultured for 18 days, then dissociated into single cells
for colony forming assay in methylcellulose (H4434 Stem Cell
Technologies). 104 EB derived cells per 1.5 mlmethylcellulose.
Colonies were scored 14 days after plating.
Retinoid acid induced differentiation and TNFα
treatment
hES cells cultured on MEFs were passaged onto Matrigel (BD
Biosciences) and cultured in mTeSR (Stem Cell Technologies)
for three days followed by 10 days of culture in differentia-
tion media: DMEM (Lonza), 20% fetal calf serum (Lonza),200 μM L-glutamine (Invitrogen), 100 μM non-essential amino
acid (Invitrogen), 100 μM sodium pyruvate (Invitrogen) and
10 μM retinoic acid (Sigma). After 10 days of differentiation,
10 ng/ml rhTNFα (R&D) treatment was performed and cells
were harvested for protein analysis.
Disclosure of potential conflict of interest
G. Q. Daley is on the Scientific Advisory Boards for iPierian,
Epizyme, Solasia, and MPM Capital and has lectured for
Johnson & Johnson. The rest of the authors have declared
they have no conflict of interest.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.12.007.
Acknowledgments
This study was supported by the Foundation for Anemia Re-
search, Alex's Lemonade Stand, the Harvard Stem Cell
Institute, the Burroughs Wellcome Fund, the Leukemia and
Lymphoma Society, and the Howard Hughes Medical Insti-
tute (to G.Q.D.). This is also supported by a grant from the
Harvard Stem Cell Institute and Charles H. Hood Foundation
(to P.H.L.).
References
Abinun, M., Spickett, G., Appleton, A.L., Flood, T., Cant, A.J.,
1996. Anhidrotic ectodermal dysplasia associated with specific
antibody deficiency. Eur. J. Pediatr. 155 (2), 146–147.
Clarke, A., Phillips, D.I., Brown, R., Harper, P.S., 1987. Clinical
aspects of X-linked hypohidrotic ectodermal dysplasia. Arch.
Dis. Child. 62 (10), 989–996.
Dimos, J.T., Rodolfa, K.T., Niakan, K.K.,Weisenthal, L.M., Mitsumoto,
H., Chung, W., Eggan, K., 2008. Induced pluripotent stem cells
generated from patients with ALS can be differentiated into
motor neurons. Science (New York, N.Y.) 321 (5893), 1218–1221.
Doffinger, R., Smahi, A., Bessia, C., Geissmann, F., Feinberg, J.,
Durandy, A., Casanova, J.L., 2001. X-linked anhidrotic ectodermal
dysplasia with immunodeficiency is caused by impaired NF-kappaB
signaling. Nat. Genet. 27 (3), 277–285.
Egli, D., Sandler, V.M., Shinohara, M.L., Cantor, H., Eggan, K., 2009.
Reprogramming after chromosome transfer intomouse blastomeres.
Curr. Biol. 19 (16), 1403–1409.
Gilmore, T.D., 2006. Introduction to NF-kappaB: players, pathways,
perspectives. Oncogene 25 (51), 6680–6684.
Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-
Bourget, J., Zhang, K., 2011. Somatic coding mutations in human
induced pluripotent stem cells. Nature 471 (7336), 63–67.
Hall, L.L., Byron, M., Butler, J., Becker, K.A., Nelson, A., Amit, M.,
Lawrence, J.B., 2008. X-inactivation reveals epigenetic anoma-
lies in most hESC but identifies sublines that initiate as expected.
J. Cell. Physiol. 216 (2), 445–452.
Hanson, E.P., Monaco-Shawver, L., Solt, L.A., Madge, L.A., Banerjee,
P.P., May, M.J., Orange, J.S., 2008. Hypomorphic nuclear factor-
kappaB essential modulator mutation database and reconstitution
system identifies phenotypic and immunologic diversity. J. Allergy
Clin. Immunol. 122 (6), 1169–1177 e1116.
Huntley, C.C., Ross, R.M., 1981. Anhidrotic ectodermal dysplasia
with transient hypogammaglobulinemia. Cutis 28 (4), 417–419
419.
Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R.,
Narva, E., Otonkoski, T., 2011. Copy number variation and
415Derivation of human embryonic stem cells with NEMO deficiencyselection during reprogramming to pluripotency. Nature 471
(7336), 58–62.
Jain, A., Ma, C.A., Liu, S., Doffinger, R., Smahi, A., Bessia, C.,
Casanova, J.L., 2001. Specific missense mutations in NEMO result
in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia;
X-linked anhidrotic ectodermal dysplasia with immunodeficiency
is caused by impaired NF-kappaB signaling. Nat. Genet. 2 27(3;
3), 223; 277–228; 285.
Kang, H.B., Kim, Y.E., Kwon, H.J., Sok, D.E., Lee, Y., 2007. Enhance-
ment of NF-kappaB expression and activity upon differentiation of
human embryonic stem cell line SNUhES3. Stem Cells Dev. 16 (4),
615–623.
Lengner, C.J., Gimelbrant, A.A., Erwin, J.A., Cheng, A.W., Guenther,
M.G., Welstead, G.G., Mitalipova, M., 2010. Derivation of pre-X
inactivation human embryonic stem cells under physiological
oxygen concentrations. Cell 141 (5), 872–883.
Lerou, P.H., Yabuuchi, A., Huo, H., Miller, J.D., Boyer, L.F., Schlaeger,
T.M., Daley, G.Q., 2008a. Derivation and maintenance of human
embryonic stem cells from poor-quality in vitro fertilization
embryos. Nat. Protoc. 3 (5), 923–933.
Lerou, P.H., Yabuuchi, A., Huo, H., Takeuchi, A., Shea, J., Cimini,
T., Daley, G.Q., 2008b. Human embryonic stem cell derivation
from poor-quality embryos. Nat. Biotechnol. 26 (2), 212–214.
Mateizel, I., De Temmerman, N., Ullmann, U., Cauffman, G., Sermon,
K., Van de Velde, H., Van Steirteghem, A., 2006. Derivation of
human embryonic stem cell lines from embryos obtained after
IVF and after PGD for monogenic disorders. Hum. Reprod. (Oxford,
England) 21 (2), 503–511.
Orange, J.S., Brodeur, S.R., Jain, A., Bonilla, F.A., Schneider, L.C.,
Kretschmer, R., Geha, R.S., 2002. Deficient natural killer cell
cytotoxicity in patients with IKK-gamma/NEMO mutations.
J. Clin. Invest. 109 (11), 1501–1509.
Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura,
A., Daley, G.Q., 2008. Disease-specific induced pluripotent stem
cells. Cell 134 (5), 877–886.Raya, A., Rodriguez-Piza, I., Guenechea, G., Vassena, R., Navarro, S.,
Barrero, M.J., Izpisua Belmonte, J.C., 2009. Disease-corrected
haematopoietic progenitors from Fanconi anaemia induced
pluripotent stem cells. Nature 460 (7251), 53–59.
Rudolph, D.Y.W.,Wakeham, A., Rudolph, B., Nallainathan, D., Potter,
J., Elia, A.J., Mak, T.W., 2000. Severe liver degeneration and lack
of NF-kappaB activation in NEMO/IKKgamma-deficient mice.
Genes Dev. 14 (7), 854–862.
Shen, Y., Matsuno, Y., Fouse, S.D., Rao, N., Root, S., Xu, R., Fan,
G., 2008. X-inactivation in female human embryonic stem cells
is in a nonrandom pattern and prone to epigenetic alterations.
Proc. Natl. Acad. Sci. U. S. A. 105 (12), 4709–4714.
Silva, S.S., Rowntree, R.K., Mekhoubad, S., Lee, J.T., 2008. X-
chromosome inactivation and epigenetic fluidity in human
embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 105 (12),
4820–4825.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by
defined factors. Cell 126 (4), 663–676.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A.,
Swiergiel, J.J., Marshall, V.S., Jones, J.M., 1998. Embryonic
stem cell lines derived from human blastocysts. Science (New
York, N.Y.) 282 (5391), 1145–1147.
Verlinsky, Y., Strelchenko, N., Kukharenko, V., Rechitsky, S.,
Verlinsky, O., Galat, V., Kuliev, A., 2005. Human embryonic
stem cell lines with genetic disorders. Reprod. Biomed. Online
10 (1), 105–110.
Zhu, H., Lensch, M.W., Cahan, P., Daley, G.Q., 2011. Investigating
monogenic and complex diseases with pluripotent stem cells.
Nat. Rev. Genet. 12 (4), 266–275.
Zonana, J., Elder, M.E., Schneider, L.C., Orlow, S.J., Moss, C.,
Golabi, M., Ferguson, B.M., 2000. A novel X-linked disorder
of immune deficiency and hypohidrotic ectodermal dysplasia
is allelic to incontinentia pigmenti and due to mutations in IKK-
gamma (NEMO). Am. J. Hum. Genet. 67 (6), 1555–1562.
